Home Online Features Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
Lilly’s tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
HO
Press Releases
Eli Lilly and Company  
November 16, 2024

Lilly’s tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social